NCT01498978View on ClinicalTrials.gov

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 6, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

January 19, 2019

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
BIOLOGICAL

ipilimumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

97239

OHSU Knight Cancer Institute, Portland

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT01498978 - Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter